Phase 1 N=4 Pancreatic Islet Cell Transplantation
Type 1 Diabetes
Primary: Achievement of Insulin Independence at 12-month Post Transplant — 1 participant
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
Diabetes Mellitus, Type 1
Primary: Insulin Independence. — 2 Participants
Phase 2 N=36 Islet Transplantation for Type 1 Diabetes
Diabetes Mellitus, Insulin-Dependent
Primary: Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation. — 44; 14; 17; 14…
Phase 2 N=7 Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
Diabetes Mellitus, Type I
Primary: Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point…
Phase 2 N=3 Allogeneic Islet Cells Transplanted Onto the Omentum
Type 1 Diabetes Mellitus · Hypoglycemia · Hypoglycemia Unawareness
Primary: A1c </= 6.5% and no Severe Hypoglycemia — 0.667 Proportion of participants
Phase 2 N=8 Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression
Diabetes Mellitus, Type 1
Primary: The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation — 5 participants
Phase 2 N=5 Islet Transplantation Using Abatacept
Type 1 Diabetes Mellitus
Primary: The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation — 4; 1 participants
Phase 2 N=10 Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression
Diabetes Mellitus, Type 1
Primary: Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation — 4; 5 participants
N/A N=14 Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation
Chronic Pancreatitis · Diabetes Mellitus
Primary: Study Period: Average Serum BG — 130; 111 mg/dL — p=0.003
Phase 4 N=83 Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
Pancreatitis · Diabetes
Primary: Insulin Independence — 42; 45 percentage of participants
Phase 2 N=14 Islet Allotransplantation With Steroid Free Immunosuppression
Type 1 Diabetes · Hypoglycemia · Metabolic Diseases
Primary: Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year — 71 Percentage of patients
Phase 4 N=43 Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Phase 4 N=6 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
Phase 2 N=48 Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
Phase 2 N=8 Incretin Effect and Use After Clinical Islet Transplantation
Type 1 Diabetes
Primary: The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy. — 0.25 proportion of participants — p=< 0.05
Phase 1 N=7 Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant
Type 1 Diabetes · Type 2 Diabetes
Primary: Number of Participants Who Experienced Adverse Events — 1; 7 participants
Phase 4 N=36 A Clinical Trial to Prevent New Onset Diabetes After Transplantation
Prevention of New Onset Diabetes Among Kidney Transplant Patients
Primary: The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation — 3; 1 Participants — p=0.87
Phase 2 N=3 Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
Type 1 Diabetes Mellitus
Primary: Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia — 3 participants
N/A N=7 CGM Use in Islet Transplant Recipients
Islet Transplantation · Type1 Diabetes Mellitus
Primary: Percentage Time in Range 70-180 mg/dL by CGM — 77 percentage of CGM readings 70-180mg/dL
Phase 3 N=104 Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Pancreatectomy for Chronic Pancreatitis
Primary: Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant. — 20.0; 21.2 Percentage of participants…
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Early Phase 1 N=11 Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
Phase 2 N=9 Reparixin in Pancreatic Islet Transplantation
Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
Primary: The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5 — 0; 0 percentage of patients
Phase 2 N=2 Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
Kidney Transplant · Type 1 Diabetes
Primary: The Proportion of GLASSIA Versus Control CIT06 Subjects Achieving Insulin Independence After First Infusion of Single Donor Islets. — 0; 2; 2; 1 Participants
N/A N=10 Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes
Hyperinsulinism · Diabetes · Pancreatic Diseases
Primary: Mean Plasma Glucose Level. — 149.666118; 162.574753 mg/dL
Phase 3 N=48 Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
Islet Transplantation in Diabetes Mellitus Type 1
Primary: Area Under the Curve (AUC) for the Serum C-peptide Level During the First 2 Hours of an MMTT (Mixed Meal Tolerance Test), Normalized by the Number of Islet Equivalent…
Phase 2 N=60 Fecal Microbiota Transplantation for Pancreatitis
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
Early Phase 1 N=9 Adrenergic System in Islet Transplantation
Type1diabetes · Hypoglycemia · Hypoglycemia Unawareness
Primary: C-PEPTIDE Suppression During Hyperinsulinemia Euglycemia. — 0.51; 0.56; 0.59 ng/mL
Phase 2 N=10 Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation
Type 1 Diabetes
Primary: The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion — 4 participants